CXR and Taconic Agree Global Marketing of HRN™ Model
News Mar 30, 2007
CXR Biosciences Ltd. has announced an agreement to provide the Hepatic Reductase Null (HRN™) mouse commercially. The HRN™ mouse will join Taconic’s portfolio of Taconic Transgenic Models™, vital transgenic research models readily available in typical study quantities.
Taconic Transgenic Models™ are sold with enabling use rights to the technologies embodied in the models. CXR will continue to offer client services using the HRNTM mouse, but thanks to this agreement, customers will now be able to purchase this useful model for use at their own facilities.
CXR’s patented HRN™ mouse is a model that has essentially no hepatic cytochrome P450 activity (1), the major enzyme system involved in drug disposition in both mice and humans. This valuable mouse represents a significantly improved in vivo model for the assessment of the role of metabolism in determining the efficacy, bioavailability and toxicity of drug candidates.
In addition to its benefits as a problem solving tool, the HRN™ mouse allows in-vivo efficacy evaluation of new compounds using much smaller quantities of material due to the lack of first pass metabolism. Using this model, pharmaceutical companies can demonstrate in vivo efficacy at earlier stages, without the need for chemistry scale up, thus enabling more throughput of compounds.
When compared to the effects in normal mice, the HRN™ model also allows easy discrimination between parent compounds and metabolites for both efficacy and toxicity. Overall, the HRN™ mouse model is an essential new tool in drug discovery and preclinical development for the study of cytochrome P450 metabolism and drug disposition. Use of the HRN™ mouse will improve the lead selection and development process significantly.
Donna Gulezian, Taconic’s Director of Product Management, said “Working together with CXR to add the HRN™ mouse to Taconic’s growing portfolio and speeding its commercialization to market represents our commitment to enhancing and accelerating access to the most relevant models for the development of safe new drugs.
Scientists already employing Taconic’s MDR and other drug transporter knockouts to address absorption and disposition questions now have a new complementary tool at their disposal that has the potential to transform the way we evaluate the contribution of drug metabolism to the efficacy and toxicity of drugs in development.”
Dr. Tom Shepherd, CEO of CXR Biosciences, said,”Taconic is a leader of supplying transgenic mice worldwide and is a natural partner for CXR. Large pharmaceutical companies have been using the HRNTM mouse by sending their compounds to CXR for testing. Following this agreement, customers will soon be able to buy mice directly from Taconic and use the model in their own facilities.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019